1. Home
  2. CRMT vs NCEL Comparison

CRMT vs NCEL Comparison

Compare CRMT & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo America's Car-Mart Inc

CRMT

America's Car-Mart Inc

HOLD

Current Price

$3.26

Market Cap

19.7M

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

HOLD

Current Price

$3.48

Market Cap

22.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRMT
NCEL
Founded
1981
2008
Country
United States
Switzerland
Employees
N/A
4
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.7M
22.0M
IPO Year
2026
N/A

Fundamental Metrics

Financial Performance
Metric
CRMT
NCEL
Price
$3.26
$3.48
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$29.50
N/A
AVG Volume (30 Days)
644.0K
33.1K
Earning Date
06-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,281,502,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.92
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.38
$1.83
52 Week High
$48.79
$5.12

Technical Indicators

Market Signals
Indicator
CRMT
NCEL
Relative Strength Index (RSI) 42.68 41.65
Support Level $1.38 $2.58
Resistance Level $4.49 $3.70
Average True Range (ATR) 0.65 0.34
MACD 0.15 -0.07
Stochastic Oscillator 21.20 7.32

Price Performance

Historical Comparison
CRMT
NCEL

About CRMT America's Car-Mart Inc

America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: